Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin biomarker and clinical response in heart failure
TCTR20260904003Recruiting
- Sponsor
- Wanwarang Wongcharoen
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Wanwarang Wongcharoen. Primary endpoints: NT-proBNP at baseline, NT-proBNP at 3 months and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on TCTR20260904003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260904003.